News & Articles

FEATURED ARTICLE

MRGPRX2: A Promising Target for Antibody Discovery in Allergy and Pain Disorders

Recent studies have shown that various drugs, including small molecules, opioids, and antibiotics, can activate MRGPRX2 (Mas-related G-protein coupled receptor X2), leading to mast cell degranulation and...

Browse articles by topic:

The Ideal Choice for Low dsRNA: MaxPure™ T7 RNA Polymerase

July 16, 2024

7 min read

Exciting news of mRNA vaccine research against monkeypox has been coming out since the beginning of 2024: February 15, the...

Inflammatory Target: TSLP

July 2, 2024

4 min read

Thymic Stromal Lymphopoietin (TSLP), is a pleiotropic cytokine of the IL-2 family, closely related to IL-7, playing a significant role...

Gene Editing Drugs from the EMA Review Perspective

June 25, 2024

5 min read

Casgevy, the world's first drug based on CRISPR/Cas9 gene-editing technology, was approved for market release at the end of 2023,...

New Momentum for Integrin Drugs: Integrin αvβ6

June 19, 2024

4 min read

Function and Signaling Pathway of Integrin αvβ6 Integrin αvβ6 (hereinafter referred to as αvβ6) belongs to the integrin family of...

GDF-8 (Myostatin) antibody Apitegromab achieves success in Phase III clinical trial

June 13, 2024

4 min read

On October 7, 2024, Scholar Rock announced that the Phase III clinical trial (SAPPHIRE) of Apitegromab (SRK-015) met its primary...

Fat Loss and Muscle Gain: Targeting the Activin Signaling Pathway

May 30, 2024

4 min read

In July 2023, Eli Lilly made a nearly $2 billion bet on Versanis' ActRII inhibitor, Bimagrumab, citing its ability to...

FDA New Guidelines Pave the Way for Gene Editing Drug Development

April 24, 2024

2 min read

FDA Official Guidelines On January 31, 2024, the FDA CBER officially released the "Human Gene Therapy Products Incorporating Human Genome...

MSLN Targeted Drugs Entering the Fast Lane

February 29, 2024

5 min read

Since December 2023, there have been several positive updates about drugs targeting MSLN. On December 19th, RemeGen announced that the...

Base Editing Technology Leads a New Chapter in Drug Development

February 14, 2024

5 min read

Since its debut in 2016, base editing technology has opened up new perspectives and methods for drug development with its...

Deciphering LY6G6D - An Emerging Target in Colorectal Cancer

February 7, 2024

4 min read

Colorectal cancer (CRC) is recognized as one of the most common and life-threatening malignancies, with an increasing proportion of advanced...

RNP, an emerging powerful tool for gene delivery

February 2, 2024

5 min read

Through decades of rapid development, gene editing technology has officially entered the CRISPR 2.0 era, with new technologies such as...

Focusing on the Neuroendocrine Tumor Target SEZ6

January 2, 2024

4 min read

Neuroendocrine neoplasms/tumors (NENs or NETs) are rare tumors that originate from specialized cells called neuroendocrine cells. These cells have characteristics...

1 2 3 4 5